Stay updated on Magrolimab Combo in AML Clinical Trial
Sign up to get notified when there's something new on the Magrolimab Combo in AML Clinical Trial page.

Latest updates to the Magrolimab Combo in AML Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the magrolimab AML study is available with its study details and posted results, including that the trial was terminated for futility and is no longer recruiting.SummaryDifference100%

- Check15 days agoChange DetectedThe site revision label changed from v3.7.2 to v3.8.0, while the study-record area continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA banner announces NIH’s transition-related terminology update, and the site revision changes from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check43 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

- Check57 days agoChange DetectedSponsor branding is removed and key study documents are deleted from the page, along with related metadata under Study Documents. This alters the availability of sponsor context and foundational materials describing the trial's design and analysis plan.SummaryDifference17%

Stay in the know with updates to Magrolimab Combo in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab Combo in AML Clinical Trial page.